These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 10506603

  • 1. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
    Leung PP, Tannock IF, Oza AM, Puodziunas A, Dranitsaris G.
    J Clin Oncol; 1999 Oct; 17(10):3082-90. PubMed ID: 10506603
    [Abstract] [Full Text] [Related]

  • 2. Cost effectiveness of treatment options in advanced breast cancer in the UK.
    Brown RE, Hutton J, Burrell A.
    Pharmacoeconomics; 2001 Oct; 19(11):1091-102. PubMed ID: 11735676
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N.
    Health Technol Assess; 2001 Oct; 5(32):1-195. PubMed ID: 12065068
    [Abstract] [Full Text] [Related]

  • 5. [A medico-economic evaluation of second line chemotherapy in metastatic breast cancer: comparison between docetaxel, paclitaxel, and vinorelbine].
    Launois RJ, Reboul-Marty JM, Bonneterre J.
    Bull Cancer; 1997 Jul; 84(7):709-21. PubMed ID: 9339197
    [Abstract] [Full Text] [Related]

  • 6. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine.
    Launois R, Reboul-Marty J, Henry B, Bonneterre J.
    Pharmacoeconomics; 1996 Nov; 10(5):504-21. PubMed ID: 10169397
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
    Clegg A, Scott DA, Hewitson P, Sidhu M, Waugh N.
    Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients.
    Brown RE, Hutton J.
    Anticancer Drugs; 1998 Nov; 9(10):899-907. PubMed ID: 9890701
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer: a multicenter phase II study.
    Gómez-Bernal A, Cruz JJ, García-Palomo A, Arizcun A, Pujol E, Diz P, Martín G, Fonseca E, Sánchez P, Rodríguez C, del Barco E, López Y.
    Am J Clin Oncol; 2003 Apr; 26(2):127-31. PubMed ID: 12714881
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer.
    Airoldi M, Cattel L, Pedani F, Marchionatti S, Tagini V, Bumma C, Recalenda V.
    Acta Oncol; 2003 Apr; 42(3):186-94. PubMed ID: 12852694
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.